Zenas BioPharma Secures Up to $300 Million Funding Deal with Royalty Pharma for Obexelimab Development and Commercialization

Reuters

2025/09/02

Zenas BioPharma Secures Up to $300 Million Funding Deal with Royalty Pharma for Obexelimab Development and Commercialization

Zenas BioPharma Inc. has entered into a funding agreement with Royalty Pharma for up to $300 million to support the development and potential U.S. commercial launch of obexelimab, a treatment for IgG4-Related Disease and other autoimmune conditions. The agreement includes an initial $75 million upfront payment, with additional funding contingent on the success of the Phase 3 INDIGO trial and U.S. FDA approvals for IgG4-RD and SLE. In return, Royalty Pharma will receive a 5.5% royalty on worldwide net sales of obexelimab. This partnership aims to accelerate the clinical and commercial advancement of obexelimab, reflecting a significant opportunity in the treatment of autoimmune diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521427-en) on September 02, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2564809631"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564809631\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564809631?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-02 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564809631","market":"nz","top_or_hot":-1,"title":"Zenas BioPharma Secures Up to $300 Million Funding Deal with Royalty Pharma for Obexelimab Development and Commercialization","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zenas BioPharma Secures Up to $300 Million Funding Deal with Royalty Pharma for Obexelimab Development and Commercialization\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ZBIO\">Zenas BioPharma Inc.</a> has entered into a funding agreement with Royalty Pharma for up to $300 million to support the development and potential U.S. commercial launch of obexelimab, a treatment for IgG4-Related Disease and other autoimmune conditions. The agreement includes an initial $75 million upfront payment, with additional funding contingent on the success of the Phase 3 INDIGO trial and U.S. FDA approvals for IgG4-RD and SLE. In return, Royalty Pharma will receive a 5.5% royalty on worldwide net sales of obexelimab. This partnership aims to accelerate the clinical and commercial advancement of obexelimab, reflecting a significant opportunity in the treatment of autoimmune diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521427-en) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zenas BioPharma Secures Up to $300 Million Funding Deal with Royalty Pharma for Obexelimab Development and Commercialization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZenas BioPharma Secures Up to $300 Million Funding Deal with Royalty Pharma for Obexelimab Development and Commercialization\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-02 19:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zenas BioPharma Secures Up to $300 Million Funding Deal with Royalty Pharma for Obexelimab Development and Commercialization\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ZBIO\">Zenas BioPharma Inc.</a> has entered into a funding agreement with Royalty Pharma for up to $300 million to support the development and potential U.S. commercial launch of obexelimab, a treatment for IgG4-Related Disease and other autoimmune conditions. The agreement includes an initial $75 million upfront payment, with additional funding contingent on the success of the Phase 3 INDIGO trial and U.S. FDA approvals for IgG4-RD and SLE. In return, Royalty Pharma will receive a 5.5% royalty on worldwide net sales of obexelimab. This partnership aims to accelerate the clinical and commercial advancement of obexelimab, reflecting a significant opportunity in the treatment of autoimmune diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521427-en) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL90KTqs:1","article_id":"2564809631","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564809631","pubTimestamp":1756811117,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zenas BioPharma Inc. has entered into a funding agreement with Royalty Pharma for up to $300 million to support the development and potential U.S. commercial launch of obexelimab, a treatment for IgG4-Related Disease and other autoimmune conditions. The agreement includes an initial $75 million upfront payment, with additional funding contingent on the success of the Phase 3 INDIGO trial and U.S. FDA approvals for IgG4-RD and SLE. In return, Royalty Pharma will receive a 5.5% royalty on worldwide net sales of obexelimab. This partnership aims to accelerate the clinical and commercial advancement of obexelimab, reflecting a significant opportunity in the treatment of autoimmune diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ze","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","BK4139":"生物科技","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","RPRX":"Royalty Pharma plc","ZBIO":"Zenas BioPharma Inc.","BK4007":"制药","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"Zenas BioPharma与Royalty Pharma达成高达3亿美元的融资协议，用于Obexelimab的开发和商业化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RPRX":0.9,"NDAQ":0.9,"ZBIO":0.9},"content_text":"Zenas BioPharma Secures Up to $300 Million Funding Deal with Royalty Pharma for Obexelimab Development and Commercialization\n    \n\nZenas BioPharma Inc. has entered into a funding agreement with Royalty Pharma for up to $300 million to support the development and potential U.S. commercial launch of obexelimab, a treatment for IgG4-Related Disease and other autoimmune conditions. The agreement includes an initial $75 million upfront payment, with additional funding contingent on the success of the Phase 3 INDIGO trial and U.S. FDA approvals for IgG4-RD and SLE. In return, Royalty Pharma will receive a 5.5% royalty on worldwide net sales of obexelimab. This partnership aims to accelerate the clinical and commercial advancement of obexelimab, reflecting a significant opportunity in the treatment of autoimmune diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521427-en) on September 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}